Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
Plaza, Vicente (Institut d'Investigació Biomèdica Sant Pau)
Domínguez-Ortega, Javier (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
González-Segura Alsina, Diego (Chiesi España)
Lo Re, Daniele (Universidad de Granada)
Sicras-Mainar, Antoni (Atrys Health. SA)
Universitat Autònoma de Barcelona

Fecha:	2023
Resumen:	Adding LAMA to LABA/ICS is recommended to improve control in patients with persistent asthma. This observational, retrospective, before-and-after study considered patients diagnosed with asthma who started LABA/ICS + LAMA treatment (triple therapy, TT) between 1 January 2017 and 31 December 2018 and had been treated with LABA/ICS (dual therapy, DT) in the year before. Changes in lung function and exacerbation rates, healthcare resource utilization, and healthcare and non-healthcare costs (€2019) were estimated in patients with asthma in clinical practices in Spain. Data from computerized medical records from seven Spanish regions were collected ±1 year of LAMA addition. 4740 patients (64. 1 years old [SD: 16. 3]) were included. TT reduced the incidence of exacerbations by 16. 7% (p < 0. 044) and the number of patients with exacerbations by 8. 5% (p < 0. 001) compared to previous DT. The rate of patients with severe exacerbations requiring systemic corticosteroids and their hospitalization rates significantly decreased by 22. 5% and 29. 5%. TT significantly improved FEV, FVC, and FEV/FVC, saving €571/patient for society. Younger patients with asthma (18-44 years old) and patients with severe asthma (FEV < 60%) performed better upon the initiation of TT. TT reduced asthma exacerbations, improved lung function and reduced healthcare costs vs. DT, particularly in patients requiring systemic corticosteroids to treat severe exacerbations.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Asthma ; Costs ; Dual therapy ; Exacerbations ; Long-acting muscarinic antagonists ; Triple therapy
Publicado en:	Pharmaceuticals, Vol. 16 Núm. 11 (november 2023) , p. 1609, ISSN 1424-8247

DOI: 10.3390/ph16111609
PMID: 38004474

16 p, 771.9 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados